Skip to content
PeptidesEncyclopedia
Informational, not medical advice

This is an approved / prescription medicine. Do not use without a prescription and medical supervision.

EMA-approvedaka PegIntron

Peginterferon alfa-2b — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Peginterferon alfa-2b (also known as PegIntron) is a peptide catalogued under Immune (PEG-IFN-α). Neutral reference entry; EU status: EU-approved prescription medicine.

What is Peginterferon alfa-2b?

Peginterferon alfa-2b is interferon alfa-2b conjugated to polyethylene glycol, which extends its half-life and allows less frequent dosing than conventional interferon. It is an approved biologic marketed as PegIntron (historically for chronic hepatitis C, usually with ribavirin) and as Sylatron for adjuvant treatment of resected high-risk melanoma.

Supporting evidence is high-quality and human, including the phase III EORTC 18991 melanoma trial and randomised registration trials in hepatitis C and B.

How does Peginterferon alfa-2b work?

Like unmodified interferon alfa-2b, the pegylated form signals through the type I interferon receptor and JAK-STAT pathway to drive antiviral, antiproliferative, and immunostimulatory gene programmes.

PEGylation slows clearance and sustains plasma exposure, giving more constant interferon receptor engagement between doses.

What does the research say about Peginterferon alfa-2b?

  • As adjuvant therapy it improved recurrence-free survival versus observation in resected stage III melanoma in the EORTC 18991 phase III trial. [1]
  • Combined with ribavirin it achieved higher sustained virologic response than standard interferon alfa-2b plus ribavirin in chronic hepatitis C. [3]
  • In HBeAg-positive chronic hepatitis B it increased HBeAg loss, with or without added lamivudine. [5]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

  • [1] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial — Eggermont AM et al., Lancet 2008. (Randomised controlled trial (phase III, EORTC 18991))
  • [2] Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma — Eggermont AM et al., Journal of Clinical Oncology 2012. (Randomised controlled trial (long-term follow-up))
  • [3] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial — Manns MP et al., Lancet 2001. (Randomised controlled trial)
  • [4] A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C — Lindsay KL et al., Hepatology 2001. (Randomised controlled trial)
  • [5] Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial — Janssen HL et al., Lancet 2005. (Randomised controlled trial)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

Regimens have been weight-based and given by subcutaneous injection, typically weekly for hepatitis indications (with ribavirin for hepatitis C) and as a distinct multi-year weekly adjuvant schedule for melanoma under the Sylatron label.

This is contextual background only, not a dosing guide; dosing and monitoring must be set by a treating physician.

Side effects & safety profile

As an interferon-alpha product, peginterferon alfa-2b carries the same FDA boxed warning for fatal or life-threatening neuropsychiatric, autoimmune, ischaemic, and infectious disorders, and requires close monitoring with discontinuation for persistently severe events.

Common toxicities mirror conventional interferon: flu-like symptoms, fatigue, depression, neutropenia and thrombocytopenia, and thyroid or hepatic abnormalities.

It is prescription-only and must be given under specialist supervision with baseline and periodic laboratory and psychiatric assessment.

Stacking & combinations

Evidence-based combinations are limited to approved partners such as ribavirin (hepatitis C) or lamivudine (hepatitis B), and no combination with unapproved research compounds is supported.

Finding Peginterferon alfa-2b vendors

Finding Peginterferon alfa-2b vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Sign in to review

Frequently asked questions

It is the same interferon protein attached to a polyethylene glycol chain, which lengthens its half-life so it can be dosed less often, usually once weekly.

References

  1. [1] Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial — Eggermont AM et al., Lancet 2008. PMID: 18620949. View sourceStudy: Randomised controlled trial (phase III, EORTC 18991)Adjuvant pegylated interferon alfa-2b significantly improved recurrence-free survival versus observation in resected stage III melanoma.
  2. [2] Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma — Eggermont AM et al., Journal of Clinical Oncology 2012. PMID: 23008300. View sourceStudy: Randomised controlled trial (long-term follow-up)The recurrence-free survival benefit was sustained on long-term follow-up and was most pronounced in patients with ulcerated primaries and microscopic nodal disease.
  3. [3] Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial — Manns MP et al., Lancet 2001. PMID: 11583749. View sourceStudy: Randomised controlled trialPeginterferon alfa-2b plus ribavirin produced higher sustained virologic response rates than conventional interferon alfa-2b plus ribavirin.
  4. [4] A randomized, double-blind trial comparing pegylated interferon alfa-2b to interferon alfa-2b as initial treatment for chronic hepatitis C — Lindsay KL et al., Hepatology 2001. PMID: 11481625. View sourceStudy: Randomised controlled trialPegylated interferon alfa-2b monotherapy achieved higher sustained response rates than standard interferon alfa-2b in chronic hepatitis C.
  5. [5] Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial — Janssen HL et al., Lancet 2005. PMID: 15639293. View sourceStudy: Randomised controlled trialPeginterferon alfa-2b increased HBeAg loss in HBeAg-positive chronic hepatitis B, with no significant added benefit from lamivudine at follow-up.
This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.